Microdosing GLP-1/GIP Peptides These molecules didn't start as weight-loss drugs, and at sub-therapeutic doses their strongest signal may not be the scale at all — it's inflammation, endothelial function, and organ protection. Semaglutide and tirzepatide are usually framed as appetite drugs. But GIP and GLP-1 receptors sit on the heart, kidney, liver, cartilage, mast cells, and T-cells — tissue that has nothing to do with hunger. Microdosing asks a different question than the pharmaceutical industry's high-dose, weight-loss-first framing: can we access those receptor effects — lower inflammation, better insulin signaling, improved endothelial function — at doses well below what's needed to move the scale? The honest answer is: probably, in several organ systems, but the formal microdose-specific trials are only just getting underway. A Brief History — How We Got Here GLP-1/GIP are found naturally in our body. The were discovered after observatio...